SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001618835-23-000016
Filing Date
2023-03-14
Accepted
2023-03-14 09:00:32
Documents
16
Period of Report
2023-03-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K evfm-20230313.htm   iXBRL 8-K 76410
2 EX-10.1 evfmgspapipen-wmarch2023.htm EX-10.1 366782
3 EX-10.2 evfm-formofnotemarch2023.htm EX-10.2 363210
4 EX-10.3 evfm-formofwarrantmarch2023.htm EX-10.3 236128
5 EX-10.4 evfm-rranotexwarrantmarch2.htm EX-10.4 196237
  Complete submission text file 0001618835-23-000016.txt   1618332

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evfm-20230313.xsd EX-101.SCH 1896
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evfm-20230313_lab.xml EX-101.LAB 23892
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evfm-20230313_pre.xml EX-101.PRE 12519
10 EXTRACTED XBRL INSTANCE DOCUMENT evfm-20230313_htm.xml XML 10798
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 23729316
SIC: 2834 Pharmaceutical Preparations